Effect of Antihypertensive Agents Over Sleep Apnea

• Status: Completed
• Trial end date: 2016-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Obstructive sleep apnea and hypertension are well-known cardiovascular risk factors. Their control could reduce the burden of heart disease across populations. There are several drugs to control hypertension, but the only consistently beneficial treatment to reduce apneas is continuous positive airway pressure. The demonstration that one drug could improve sleep apnea and hypertension would support a novel approach in the treatment of both diseases. The role of fluid retention in sleep apnea is known for several decades. The role of diuretics is well established in hypertension but was never appropriately tested in sleep apnea. Besides to test the efficacy of these drugs, this study will help to understand the mechanisms that link hypertension and sleep apnea and its treatment.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital de Clinicas de Porto Alegre
• Treatments: Amiloride; Amlodipine; Antihypertensive Agents; Calcium; Calcium Channel Blockers; Chlorthalidone; Diuretics

Criteria

Inclusion Criteria:

• Patients older than 40 years of age

• Stage I hypertension (140-159/90-99 mmHg) and moderate obstructive sleep apnea (10-40 apneas/hour of sleep)

Exclusion Criteria:

• Low life expectancy

• Other indications for the use of diuretics or calcium channel blocker -Intolerance or contraindications to the study drugs

• Pregnancy

• Established cardiovascular disease (myocardial infarction

• Stroke

• Heart failure)

• Use of more than one drug for hypertension

• Secondary hypertension

• Participation in other clinical trial in previous 6 months